Christine Y Lu,* Kenneth M Williams,† Lyn March,‡ James V Bertouch,§ Richard O Day¶
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Lu CY, Williams K, Day R, et al. Access to high cost drugs in Australia [editorial]. BMJ 2004; 329: 415-416.
- 2. Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000; 43: 473-484.
- 3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.
- 4. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis — the importance of disease duration. Arthritis Rheum 2000; 43: 22-29.
- 5. Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 526-529.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Richard Day is a member of the Advisory Board to sponsors of adalimumab and infliximab, but all payments are received into an audited trust account for research. Ken Williams is a member of the Advisory Board and has been an advisor to the sponsor of adalimumab (Abbott), but has not received recompense. Lyn March is chairperson of the Australian Rheumatology Association Database Steering Committee and, in this capacity, has negotiated with sponsors of etanercept, adalimumab, infliximab, anakinra and leflunomide for educational grants that have been placed in audited trust funds in the Australian Rheumatology Association and the University of Sydney. James Bertouch has been an advisor to sponsors of adalimumab, infliximab, etanercept, anakinra and leflunomide. Recompense received for clinical trials has been placed in audited hospital trust funds for use in the research activities of the Rheumatology Unit, Prince of Wales Hospital, Sydney.